Actual impact of screening for myocardial ischemia with single-photon emission tomography among patients undergoing peripheral vascular interventions. Issue 9 (September 2018)

• Record Type: Journal Article
• Authors: Corneli, Mariana; Masoli, Osvaldo; Perea, Gabriel; Meretta, Alejandro; Daquarti, Gustavo; Rosa, Daniel; Belcastro, Fernando; Henquin, Ruth; Perez Baliño, Néstor
• Is Part Of: Nuclear medicine communications. Volume 39:Issue 9(2018:Sep.)
• Publication Date: 2018-09
• Subjects: myocardial ischemia -- peripheral arterial disease -- peripheral vascular intervention -- single-photon emission tomography; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000000883
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : The present study provides actual data with regard to the prevalence of myocardial ischemia among patients under contemporary cardiovascular prevention strategies undergoing peripheral vascular interventions. We included a total of 200 consecutive patients who underwent gated single-photon emission computed tomography myocardial perfusion study between January 2012 and January 2014 as preoperative evaluation for peripheral vascular interventions at our institution. The baseline medical treatment comprised aspirin (81%), statins (79%), and β-blockers (54%). Thirty-two (16%) patients underwent carotid revascularization; 69 (34.5%) patients underwent lower limb revascularization, and 99 patients underwent aortic interventions. Twenty-six (13%) patients showed evidence of myocardial ischemia, with an extensive ischemic burden identified in seven (3.5%) patients. Within the group of patients with peripheral vasculopathy, those with lower limb arteriopathy had a higher prevalence of ischemia. According to the results of the myocardial perfusion study, the cardiology in charge indicated invasive coronary angiography in 11/26 (42%) patients with evidence of myocardial ischemia. Seven of the 11 (64%) patients who had coronary angiography were revascularized. After a mean follow-up of 24 months, no cardiovascular adverse events were detected.